Bioventix AI Stock Analysis
Want to see GB:BVXP full AI Analyst Report?
Bioventix (BVXP) AI Stock Analysis
Bioventix
(LSE:BVXP)
The score is driven primarily by top-tier financial performance (high profitability, very low leverage, and strong cash conversion). Technicals add support with a strong uptrend and positive momentum, though momentum indicators are approaching overbought levels. Valuation is also favorable, combining a moderate P/E with a very high dividend yield, while the key watch item remains the recent slowdown in revenue growth.
Bioventix (BVXP) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 102.93M
- Dividend Yield
- 7.69%
- Average Volume (3M)
- 16.25K
- Price to Earnings (P/E)
- 13.4
- Beta (1Y)
- 0.59
- Revenue Growth
- -1.10%
- EPS Growth
- 0.32%
- Country
- UK
- Employees
- 12
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Bioventix Business Overview & Revenue Model
Company Description
Bioventix PLC focuses on the development, manufacturing, and global provision of sheep monoclonal antibodies (SMAs) for various diagnostic purposes. The company's extensive product line features purified SMAs that facilitate testing for critical area...
Bioventix Financial Statement Overview
Summary
Financial quality is excellent: very strong profitability (Income Statement 92), an extremely conservative balance sheet with minimal debt (Balance Sheet 95), and strong cash conversion with consistently positive free cash flow (Cash Flow 90). The main financial risk noted is the recent slowdown/softening in revenue growth.
Income Statement
92Very PositiveBalance Sheet
95Very PositiveCash Flow
90Very Positive| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.97M | 12.97M | 13.12M | 13.61M | 12.82M | 11.72M |
| Gross Profit | 11.81M | 11.81M | 11.92M | 12.68M | 11.86M | 10.87M |
| EBITDA | 9.79M | 9.79M | 10.17M | 10.74M | 10.20M | 9.42M |
| Net Income | 7.61M | 7.61M | 7.58M | 8.10M | 8.37M | 7.67M |
Balance Sheet | ||||||
| Total Assets | 12.83M | 12.83M | 12.86M | 13.73M | 13.28M | 13.12M |
| Cash, Cash Equivalents and Short-Term Investments | 5.26M | 5.26M | 5.08M | 6.00M | 5.72M | 6.13M |
| Total Debt | 10.97K | 10.97K | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.41M | 1.41M | 1.31M | 1.73M | 1.22M | 1.30M |
| Stockholders Equity | 11.42M | 11.42M | 11.55M | 12.00M | 12.06M | 11.82M |
Cash Flow | ||||||
| Free Cash Flow | 8.02M | 8.02M | 7.01M | 8.33M | 7.89M | 7.55M |
| Operating Cash Flow | 8.09M | 8.09M | 7.03M | 8.34M | 7.90M | 7.56M |
| Investing Cash Flow | -71.60K | -71.60K | 173.16K | 186.06K | 90.51K | -11.76K |
| Financing Cash Flow | -7.84M | -7.84M | -8.12M | -8.25M | -8.30M | -7.92M |
Bioventix Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:BVXP, the sentiment is Positive. The current price of 1950.00 is above the 20-day moving average (MA) of 1919.80, above the 50-day MA of 1716.60, and above the 200-day MA of 1592.90, indicating a bullish trend. The MACD of 67.40 indicates Positive momentum. The RSI at 65.47 is Neutral, neither overbought nor oversold. The STOCH value of 43.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:BVXP.
Bioventix Peers Comparison
Overall Rating
GB:BVXP89Outperform
GB:4BB52Neutral
GB:APTA46Neutral
GB:AVCT40Underperform
GB:FAB40Underperform
GB:OBD40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 89Outperform | GBP 101.88M | 13.45 | 67.81% | 7.69% | -1.10% | 0.32% | |
| 52Neutral | GBP 100.70M | -4.53 | -316.73% | ― | -56.10% | -16.77% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | GBP 12.14M | -11.67 | -46.61% | ― | 28.35% | 57.14% | |
| 40Underperform | GBP 277.96M | -6.26 | -1293.07% | ― | ― | ― | |
| 40Underperform | GBP 5.32M | -4.29 | -97.87% | ― | 7.38% | 44.13% | |
| 40Underperform | GBP 15.46M | -0.29 | -451.74% | ― | 33.37% | 86.41% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:BVXP | Bioventix plc | 1950.00 | -37.97 | -1.91% | |
| GB:AVCT | Avacta Group plc | 57.10 | -22.90 | -28.63% | |
| GB:OBD | Oxford BioDynamics | 0.12 | -0.17 | -58.93% | |
| GB:FAB | Fusion Antibodies Plc | 4.25 | -8.00 | -65.31% | |
| GB:4BB | 4basebio UK Societas | 525.00 | -187.50 | -26.32% | |
| GB:APTA | Aptamer Group Plc | 0.35 | -0.55 | -61.11% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026
